These results identified Klotho/VEGFR2/PAK1 as a crucial molecular pathway underlying resistance to anoikis for hepatoma cells, which could open a new avenue for molecular targeting therapeutic intervention with anoikis resistance in HCC patients with metastasis. Here, PAK1 is linked to hepatocellular carcinoma.